Activity of serum alpha-amylases in cystic fibrosis

Area of Science:

• Biochemistry
• Clinical Chemistry
• Pediatric Medicine

Background:

• Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
• Alpha-amylase levels, particularly pancreatic and salivary types, are potential biomarkers for pancreatic function.
• Previous studies suggested altered salivary-type amylase in CF patients.

Purpose of the Study:

• To evaluate a new differential inhibitor method for measuring pancreatic and salivary alpha-amylases.
• To compare alpha-amylase levels in serum from cystic fibrosis patients and healthy controls.
• To assess the utility of this method in diagnosing cystic fibrosis and pancreatic disorders.

Main Methods:

• Serum samples from 46 cystic fibrosis patients (4-14 years) and 50 age-matched controls were analyzed.
• A novel assay utilizing a differential inhibitor was employed to quantify pancreatic and salivary alpha-amylase.
• Statistical analysis compared enzyme levels between the CF and control groups.

Main Results:

• Pancreatic-type alpha-amylase levels were significantly lower in cystic fibrosis patients (median 26.5 I.U./L) compared to controls (median 81.5 I.U./L) (P < 0.001).
• Salivary-type alpha-amylase levels did not confirm previous reports of elevated levels in CF patients.
• Discrepancies in salivary-type amylase findings may be attributed to differences in analytical methodologies.

Conclusions:

• The new differential inhibitor method provides a reliable way to measure pancreatic and salivary alpha-amylases.
• Lower pancreatic-type amylase is a key finding in this CF cohort.
• This assay holds promise for the diagnostic investigation of cystic fibrosis and other pancreatic conditions.